SCHEMBL207341

SCHEMBL207341

O=C(O)c1cccc(C(=O)N2CCN(C(=O)C3CC3)CC2)c1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 2/20 0.62
ADRB2 P07550 1/20 0.56
FASN P49327 1/20 0.56
LMNA P02545 3/20 0.55
TSHR P16473 3/20 0.55
MAPK1 P28482 2/20 0.55
USP2 O75604 1/20 0.55
MAPT P10636 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
ALDH1A1 P00352 2/20 0.51
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.51
MGLL Q99685 1/20 0.51
HPGD P15428 1/20 0.51
EPHX1 P07099 1/20 0.49
EPHX2 P34913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205620 0.87 ADRB2 (0.55) L3MBTL3ADRB2FASNLMNATSHR
SCHEMBL206954 0.83 RBP4 (0.57) ADRB2FASNKMT2AMEN1ALDH1A1
SCHEMBL2041901 0.81 ADRB2 (0.50) L3MBTL3ADRB2FASNLMNATSHR
SCHEMBL4696934 0.80 L3MBTL3 (0.72) L3MBTL3LMNATSHRMAPK1USP2
SCHEMBL4260025 0.80 HPGD (0.60) L3MBTL3LMNATSHRMAPK1USP2
SCHEMBL20267423 0.80 MAPK1 (0.59) L3MBTL3LMNATSHRMAPK1USP2
SCHEMBL28387311 0.79 CYP2C9 (0.64) ADRB2LMNATSHRMAPK1L3MBTL1
SCHEMBL15076720 0.79 L3MBTL3 (0.70) L3MBTL3LMNATSHRMAPK1USP2
SCHEMBL26315228 0.78 L3MBTL3 (0.64) L3MBTL3LMNATSHRMAPK1USP2
SCHEMBL23682749 0.77 L3MBTL3 (1.00) L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088760-B2 Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) BIOMARIN PHARMACEUTICAL INC. (US) 2012-01-03 US disclosed
EP-2247600-A2 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) Lead Therapeutics, Inc. (US) 2010-11-10 EP disclosed
WO-2009099736-A2 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) LEAD THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20090197863-A1 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) LEAD THERAPEUTICS, INC. (US) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197863-A1 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) PARP1, PARP2, PARP11 L3MBTL3 3984/4885ADRB2 3261/4885FASN 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.